Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy

Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy

Abstract With the incorporation of cyclin-dependent kinase inhibitors in early breast cancer (BC), a better identification of biomarkers is needed. The PROMETEO II trial aimed to evaluate the antitumor activity of palbociclib plus letrozole and to identify response biomarkers in patients with operab...

Full description

Saved in:

Bibliographic Details
Main Authors:	Sonia Pernas, Esther Sanfeliu, Guillermo Villacampa, Javier Salvador, Antonia Perelló, Xavier González, Begoña Jiménez, María Merino, Patricia Palacios, Tomás Pascual, Emilio Alba, Lorea Villanueva, Samyukta Chillara, Juan Manuel Ferrero-Cafiero, Patricia Galvan, Aleix Prat, Eva Ciruelos
Format:	Article
Language:	English
Published:	Nature Portfolio 2024-11-01
Series:	npj Breast Cancer
Online Access:	https://doi.org/10.1038/s41523-024-00710-x
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Cost-effectiveness Analysis of Ribociclib plus Letrozole versus Palbociclib plus Letrozole in the United Kingdom
by: Gaurav Suri, et al.
Published: (2019-04-01)

Letrozole and palbociclib in advanced breast cancer: Outcome from cancer institute, Chennai
by: Vijay Gnanaguru, et al.
Published: (2020-01-01)

HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumab
by: Rodrigo Sánchez-Bayona, et al.
Published: (2025-04-01)

Real-world effectiveness of palbociclib in HR+/HER2- metastatic breast cancer: a literature review
by: Emilie Adrian Christiansen, et al.
Published: (2024-12-01)

Targeting ferroptosis resistance resensitizes metastatic HR+HER2− breast cancer cells to palbociclib‐hormone therapy
by: Charles Pottier, et al.
Published: (2025-04-01)

Real-world effectiveness of palbociclib plus an aromatase inhibitor in HR+/HER2− MBC patients living in disadvantaged neighborhoods
by: Filipa Lynce, et al.
Published: (2025-07-01)

PALBOCICLIB IN COMBINATION WITH HORMONE THERAPY FOR LUMINAL HER2-NEGATIVE METASTATIC BREAST CANCER: NEW HIGHLY EFFECTIVE STRATEGY OF DRUG TREATMENT
by: E. V. Artamonova
Published: (2017-09-01)

Overall Survival With Palbociclib and Aromatase Inhibitor Versus Aromatase Inhibitor Alone in Older Patients With HR+/HER2− Metastatic Breast Cancer
by: Adam M. Brufsky, et al.
Published: (2025-04-01)

Palbociclib as an Antitumor Drug: A License to Kill
by: Agnieszka Łupicka-Słowik, et al.
Published: (2024-11-01)

Neutropenia due to palbociclib: A word of caution?
by: Raja Pramanik, et al.
Published: (2016-01-01)

Healthcare Resource Utilization and Cost Comparison Between Palbociclib, Abemaciclib, and Ribociclib Among Patients with HR+/HER2− Metastatic Breast Cancer
by: Pluard TJ, et al.
Published: (2025-03-01)

Real-world palbociclib dose modifications and clinical outcomes in patients with HR+/HER2− metastatic breast cancer: A Flatiron Health database analysis
by: Rachel M. Layman, et al.
Published: (2025-06-01)

Letrozole and clomiphene versus letrozole alone for ovulation induction in women with PCOS: a systematic review and meta-analysis
by: Karine Eskandar, et al.
Published: (2025-05-01)

Real-World, National Study of Palbociclib in HR+/HER2− Metastatic Breast Cancer: A 2.5-Year Follow-Up PALBO01/2021
by: Cristina Marinela Oprean, et al.
Published: (2025-05-01)

Nationwide real-world practice pattern and clinical data of palbociclib in HR (+), HER2 (−) metastatic breast cancer patients in Korea (KCSG BR21-15)
by: Jieun Lee, et al.
Published: (2025-08-01)

Abemaciclib and Letrozole in Metastatic Male Breast Cancer
by: Leon Schönfeld, et al.
Published: (2024-11-01)

Real-world comparison of palbociclib, abemaciclib, and dalpiciclib as first-line treatments for Chinese HR+/HER2−metastatic breast cancer patients: a multicenter study (YOUNGBC-28)
by: Yifan Chen, et al.
Published: (2024-12-01)

Microdynamic flowability for early API characterisation: A case study on Palbociclib
by: David Blanco, et al.
Published: (2025-12-01)

Letrozole Induced Hypercalcemia in a Patient with Breast Cancer
by: Suleyman Hilmi Ipekci, et al.
Published: (2014-01-01)

The Follicular Output Rate was Improved with 3-Day Letrozole Administration Compared with 5-Day Letrozole Administration Under Progestin-Primed Ovarian Stimulation
by: Wang X, et al.
Published: (2025-05-01)

A real-world study of palbociclib plus endocrine therapy with or without a short course chemotherapy in the first-line treatment of HR-positive HER2-negative metastatic breast cancer
by: Xiangjun Li, et al.
Published: (2025-07-01)

A comparative analysis of Palbociclib and Ribociclib in metastatic hormone receptor-positive, HER2-negative breast cancer: a prospective mid term follow-Up study from an Indian cohort
by: Nihanthy D. Sreenath, et al.
Published: (2025-08-01)

Adropin ameliorates reproductive dysfunctions in letrozole-induced PCOS mouse
by: Shweta Maurya, et al.
Published: (2025-03-01)

Angioneurotic edema of metastatic breast cancer patient associated with letrozole
by: Yasemin Bakkal Temi, et al.
Published: (2017-12-01)

Letrozole induced Necrotizing Cutaneous Vasculitis: A Rare Entity
by: Liza Mohapatra, et al.
Published: (2024-10-01)

Enhancing palbociclib efficacy with low toxicity in breast cancer using polycaprolactone-based nanocarriers
by: Nastaran Zerang, et al.
Published: (2025-05-01)

Surface functionalized albumin nanoparticles of palbociclib with amplified brain delivery for treating brain glioblastoma
by: Vishwanath Kurawattimath, et al.
Published: (2025-08-01)

Durable and Drastic Response to the Trastuzumab, Letrozole, Abemaciclib, and Goserelin Combination as First-Line Therapy in HER2-Positive and Hormone Receptor-Positive Metastatic Breast Cancer: A Case Report
by: Suthida Suwanvecho, et al.
Published: (2025-01-01)

Deciphering the transcriptomic landscape of early HR+/HER2− breast cancer in very young women
by: Iris Garrido‐Cano, et al.
Published: (2025-07-01)

CYCLIN-DEPENDENT KINASE INHIBITOR, PALBOCICLIB – A NEW DRUG FOR THE TREATMENT OF METASTATIC BREAST CANCER
by: E. N. Imyanitov, et al.
Published: (2017-12-01)

CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib
by: Eric Raspé, et al.
Published: (2017-05-01)

Biomarkers of palbociclib response in hormone receptor-positive advanced breast cancer from the PARSIFAL trial
by: Joan Albanell, et al.
Published: (2025-06-01)

A comparative study of ovulation induction by clomiphene citrate vs letrozole
by: Hemant Deshpande, et al.
Published: (2024-05-01)

UNEXPECTED SPONTANEOUS REGRESSION IN CLL AFTER LETROZOLE TREATMENT: COINCIDENCE OR CONNECTION?
by: Ennur Ramadan, et al.
Published: (2025-07-01)

Letrozole Potentiates Mitochondrial and Dendritic Spine Impairments Induced by β Amyloid
by: P. K.-Y. Chang, et al.
Published: (2013-01-01)

Investigation of ribociclib, abemaciclib and palbociclib resistance in ER+ breast cancer cells reveal potential therapeutic opportunities
by: Mashael Algethami, et al.
Published: (2025-08-01)

Population Pharmacokinetic and Pharmacodynamic Study of Palbociclib in Children and Young Adults with Recurrent, Progressive, or Refractory Brain Tumors
by: John C. Panetta, et al.
Published: (2024-11-01)

Molecular characterisation of the residual disease after neoadjuvant endocrine therapy in ER+/HER2- breast cancer uncovers biomarkers of tumour response
by: Joanna I. López-Velazco, et al.
Published: (2025-07-01)

Pirfenidone reduces ovarian fibrosis and improves PCOS in letrozole-induced rat model
by: Ayşe Çakır Gündoğdu, et al.
Published: (2025-06-01)

CD4+ lymphocytopenia and Pneumocystis jirovecii pneumonia in a metastatic breast cancer patient treated with palbociclib and corticosteroids
by: Shahar Dekel, et al.
Published: (2025-07-01)